Kazia Therapeutics Ltd ADR

KZIA | NASDAQ

Price Alert Chart Builder DCF Calculator

$10.92

+$0.27 (+2.54%)

At close: Sep 22, 2026, 4:00 PM ET

$10.73

-$0.19 (-1.77%)

After-hours: Sep 22, 2026, 7:35 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.54%

(1D)

Rating

Updated: Sep 12, 2026

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $17.69M

1D Range

10.71 11.25

52W Range

4.86 17.40

Valuation (TTM)

PE -1.59

PB 0.56

EV/EBITDA 2.39

Valuation (NTM)

Forward PE N/A

Forward PEG -0.04

Price Target $31.50

Cash Flow

FCF Yield -37.3%

SBC Adj. FCF Yield -37.3%

SBC Impact N/A

Margins

Gross Margin 100.0%

Operating Margin -92086.4%

FCF Margin -46038.4%

Growth (CAGR)

Revenue 3Y | 5Y -75.2% | -63.8%

Dil EPS 3Y | 5Y 71.7% | 29.5%

FCF 3Y | 5Y -4.2% | -2.7%

Returns

ROA -31.4%

ROE -116.9%

ROIC -36.2%

Financial Health

Net Cash

A$69.29M ($46.24M)

Current Ratio 2.87

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, br...

Sector Healthcare

Industry Biotechnology

Employees 6

IPO Date Jan 5, 1999

Website www.kaziatherapeutics.com

Fiscal Year July - June

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$30.50

Upside

+179.30%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞